Hogan Lovells advised OncoVerity on the deal. OncoVerity, a pioneer in applying advanced bioinformatics to drug development, announced the closing of a Series A extension financing...
You must be a Standard 1 Year member to access this content.
Hogan Lovells advised March Biosciences on the deal. March Biosciences, an emerging clinical stage biotechnology company committed to combating challenging cancers and other diseases, closed a...
You must be a Standard 1 Year member to access this content.
Hogan Lovells advised Perspective Therapeutics on the deal. Perspective Therapeutics (NYSE AMERICAN: CATX) has completed an underwritten offering of 51,515,880 shares of its common stock at...
You must be a Standard 1 Year member to access this content.
Hogan Lovells advised Perspective Therapeutics on a series of strategic transactions. Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX) has completed a series of strategic transactions with Lantheus Holdings (NASDAQ:...
You must be a Standard 1 Year member to access this content.
Hogan Lovells has advised OncoResponse on the deal. OncoResponse, a clinical-stage biotech company advancing immunotherapies for the treatment of cancer patients, closed a $50 million senior...
You must be a Standard 1 Year member to access this content.
